Array BioPharma
| Company type | Subsidiary |
|---|---|
| Nasdaq: ARRY | |
| Industry | Oncology Medication |
| Founded | 1998 |
| Founder |
|
| Headquarters | , United States |
| Revenue | $173.8 million (2018) |
| Parent | Pfizer |
| Website | www |
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
History
[edit]In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]
In November 2000, the company became a public company via an initial public offering.[2]
In June 2019, Pfizer acquired the company for approximately $11 billion.[3]
Discovery of FDA Approved Small Molecules
[edit]- MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
- TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
- BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
- KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
- KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
- VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)
References
[edit]- ^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
- ^ "Array IPO up 17%". CNN. November 17, 2000.
- ^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.
